Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

Expert opinion on biological therapy·2026
Same author

Addressing Obstetric and Gynecologic Needs in Thalassemia.

O&G open·2026
Same author

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
Same author

When cure exists but access does not.

Nature medicine·2026
Same author

Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial.

European journal of haematology·2026
Same author

Efficacy and Safety of Prophylaxis With a Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease-A WIL-31 Study Sub-Analysis.

European journal of haematology·2026
Same journal

Multi target effects of Allium macrostemon against myocardial infarction: an integrated network pharmacology, molecular docking, and experimental study.

Journal of thrombosis and thrombolysis·2026
Same journal

Comparative effectiveness of figure-of-eight suture and manual compression for femoral venous hemostasis after atrial fibrillation ablation: A grade assessed meta-analysis.

Journal of thrombosis and thrombolysis·2026
Same journal

Tissue factor-related biomarkers during combined androgen blockade in patients with prostate cancer: A brief report.

Journal of thrombosis and thrombolysis·2026
Same journal

Opioid use disorder and clinical outcomes following percutaneous coronary intervention for acute coronary syndromes.

Journal of thrombosis and thrombolysis·2026
Same journal

Sex-based differences in clinical outcomes among cardiogenic shock patients treated with mechanical circulatory support.

Journal of thrombosis and thrombolysis·2026
Same journal

IGF-1 axis: The signalling bond in cancer-associated thrombosis and cachexia?

Journal of thrombosis and thrombolysis·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Malignancy and hypercoagulability: a two-way association revisited.

Elie G Aoun1, Khaled M Musallam, Mohamad Abou-Ghazal

  • 1Department of Internal Medicine, Division of Hematology & Oncology, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon.

Journal of Thrombosis and Thrombolysis
|February 23, 2010
PubMed
Summary
This summary is machine-generated.

Malignancy and hypercoagulability have a bidirectional link. This case study explores a patient with stroke, prothrombotic mutations, and non-small cell lung cancer, highlighting this association.

More Related Videos

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Related Experiment Videos

Last Updated: Jun 16, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Area of Science:

  • Oncology
  • Hematology
  • Neurology

Background:

  • The bidirectional relationship between malignancy and hypercoagulability is increasingly recognized.
  • Hypercoagulability, a state of increased tendency to form blood clots, is a known paraneoplastic phenomenon.
  • Venous thromboembolism (VTE) is a common complication in cancer patients.

Observation:

  • A patient with a history of venous thromboembolism presented with stroke.
  • The patient was diagnosed with non-small cell lung carcinoma.
  • Genetic workup revealed prothrombotic mutations in the prothrombin and methylenetetrahydrofolate reductase genes.

Findings:

  • The patient's stroke was potentially linked to their underlying malignancy and prothrombotic genetic mutations.
  • This case illustrates the complex interplay between cancer and clotting disorders.
  • The prothrombotic state, indicated by specific gene mutations, may predispose individuals to both VTE and cancer-related complications.

Implications:

  • Understanding the link between malignancy and hypercoagulability is crucial for risk stratification and management.
  • Early detection of prothrombotic states in cancer patients may improve outcomes.
  • Further research into the mechanisms underlying cancer-associated hypercoagulability is warranted.